Sun Yat-sen University: Esophageal Squamous Cell Carcinoma trials

The registry lists 32 Esophageal Squamous Cell Carcinoma studies with Sun Yat-sen University as lead sponsor. 13 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 21Phase 3 5No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal CancerRecruitingNCT07751055Phase 2
• An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07709533Phase 2
• Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07701681Phase 2
• Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07638436Phase 2
• Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCCRecruitingNCT07177794Phase 3
• Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07086469Phase 2
• Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT06912074Phase 2
• Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)RecruitingNCT06561178
• Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)RecruitingNCT06187597Phase 2
• PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCCRecruitingNCT05737563Phase 3
• Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCCRecruitingNCT05626569Phase 2
• Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）RecruitingNCT05512520Phase 2
• PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)RecruitingNCT05357846Phase 3
• A Single-center, Single-arm Clinical Study Evaluating the Short-term Efficacy of Inflatable Mediastinoscopic-assisted Transhiatal Laparoscopic Esophagectomy for the Radical Resection of Thoracic Esophageal CancerCompletedNCT07581236Not applicable
• Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell CarcinomaActive, not recruitingNCT07374003Phase 2
• A Clinical Trial of Esophagectomy for Esophageal CarcinomaCompletedNCT06691503Phase 2
• Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT06281886Phase 2
• Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)Active, not recruitingNCT06143748Phase 2
• Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant ChemoradiotherapyActive, not recruitingNCT06061263
• Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.Active, not recruitingNCT06020885Phase 1
• Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)Active, not recruitingNCT05520619Phase 2
• Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04844385Phase 2
• Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC PatientsCompletedNCT04548440Phase 2
• Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell CarcinomaCompletedNCT04380480Phase 2
• Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell CarcinomaCompletedNCT03660449Phase 2
• Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT02964455Phase 1
• A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell CarcinomaStatus unknownNCT02915965Phase 2
• Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.CompletedNCT02606916Phase 2
• Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)Active, not recruitingNCT02465736Phase 3
• Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal CancerStatus unknownNCT02325986Phase 2
• ESI With EUS to Differentiate T3 and T4 ESCCStatus unknownNCT01930630Phase 1
• Improve the Treatment of Thoracic Esophageal CancerCompletedNCT01137123Phase 3